Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
Canova S, Ceresoli GL, Grosso F, Zucali PA, Gelsomino F, Pasello G, Mencoboni M, Rulli E, Galli F, De Simone I, Carlucci L, De Angelis A, Belletti M, Bonomi M, D'Aveni A, Perrino M, Bono F, Cortinovis DL; DIADEM groupD. Canova S, et al. ESMO Open. 2022 Dec;7(6):100644. doi: 10.1016/j.esmoop.2022.100644. Epub 2022 Dec 1. ESMO Open. 2022. PMID: 36463732 Free PMC article. Clinical Trial.
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altimari A, Gruppioni E, Fiorentino M, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A. Ruzzi F, et al. Among authors: ardizzoni a. Transl Lung Cancer Res. 2022 Nov;11(11):2216-2229. doi: 10.21037/tlcr-22-163. Transl Lung Cancer Res. 2022. PMID: 36519016 Free PMC article.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S, Gelsomino F, Rinaldi R, Muccioli L, Comito F, Di Federico A, De Giglio A, Lamberti G, Andrini E, Mollica V, D'Angelo R, Baccari F, Zenesini C, Madia P, Raschi E, Cortelli P, Ardizzoni A, Guarino M. Rossi S, et al. Among authors: ardizzoni a. J Neurol. 2023 Jun;270(6):2975-2986. doi: 10.1007/s00415-023-11625-1. Epub 2023 Feb 17. J Neurol. 2023. PMID: 36800019 Free PMC article.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: ardizzoni a. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Novel therapeutic strategies for recurrent SCLC.
Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Moliner L, et al. Among authors: ardizzoni a. Crit Rev Oncol Hematol. 2023 Jun;186:104017. doi: 10.1016/j.critrevonc.2023.104017. Epub 2023 May 5. Crit Rev Oncol Hematol. 2023. PMID: 37150311 Review.
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
Garon EB, Lu S, Goto Y, De Marchi P, Paz-Ares L, Spigel DR, Thomas M, Yang JC, Ardizzoni A, Barlesi F, Orlov S, Yoshioka H, Mountzios G, Khanna S, Bossen C, Carbini M, Turri S, Myers A, Cho BC. Garon EB, et al. Among authors: ardizzoni a. J Clin Oncol. 2024 Jan 10;42(2):180-191. doi: 10.1200/JCO.23.00910. Epub 2023 Oct 3. J Clin Oncol. 2024. PMID: 37788412 Clinical Trial.
491 results